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The role of specific biomarkers, as
predictors of post-operative complications
following flexible ureterorenoscopy (FURS),
for the treatment of kidney stones: a
single-centre observational clinical pilot-
study in 37 patients
Stephen Fôn Hughes1,2* , Alyson Jayne Moyes1,3,4, Rebecca May Lamb1,4, Peter Ella-tongwiis1,2, Christopher Bell2,5,
Ahmed Moussa2,5 and Iqbal Shergill1,2,5
Abstract
Background: The number of patients diagnosed and subsequently treated for kidney stones is increasing, and as
such the number of post-operative complications is likely to increase. At present, little is known about the role of
specific biomarkers, following flexible ureterorenoscopy (FURS) for the surgical treatment of kidney stones. The main
aim of the study was to evaluate the role of kidney and infection biomarkers, in patients undergoing FURS.
Methods: Included were 37 patients (24 males, 13 females), who underwent elective FURS, for the treatment of
kidney stones. Venous blood samples were collected from each patient: pre-operatively, and at 30 min, 2 and 4 h
post-operatively. Changes to kidney (NGAL, Cystatin-C) and infection (MPO, PCT) biomarkers was quantified by
means of ELISA, Biomerieux mini-vidas and Konelab 20 analysers.
Results: Four patients developed post-operative complications (3 - UTIs with urinary retention, 1 - urosepsis. NGAL
concentration increased significantly following FURS (p = 0.034). Although no significant changes were seen in
Cystatin C, MPO and PCT (p ≥ 0.05) some key clinical observation were noted. Limiting factors for this study were
the small number of patients recruited and restriction in blood sampling beyond 4 h.
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Conclusions: Although not confirmative, changes seen to biomarkers such as Cystatin C, NGAL and MPO in our
observational clinical pilot-study may warrant further investigation, involving larger cohorts, to fully understand the
role of these biomarkers and their potential association with post-operative complications which can develop
following FURS.
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Background
Flexible ureterorenoscopy (FURS) is an increasingly
popular procedure for the treatment of kidney stones.
The complication rate following FURS is up to 25% with
this figure likely to increase [1]. Conventionally in the
UK, patients have been monitored post-operatively using
routine blood tests, such as the full blood count, urea
and electrolyte and C reactive protein (CRP). Although
these traditional blood tests are clinically useful, they are
non-specific in nature, and fail to identify patients at in-
creased risk of developing postoperative complications,
such as infection and acute kidney injury.
At present, there is limited literature and evidence-
based reports highlighting the role of specific bio-
markers, which can monitor patients following FURS. In
turn, it is anticipated, in the future, that a specific panel
of biomarkers (or biomarker profile) may help aid clini-
cians in the monitoring of patients undergoing FURS
and could help identify or predict those individuals at in-
creased risk of developing complications post-procedure.
In the present study, we have identified specific kidney
and potential infection biomarkers that may provide
clinically important information that will aid monitoring
and subsequent managing of these patients. Cystatin C
is a cysteine proteinase inhibitor which is produced by
all nucleated cells and is has gathered increasing interest
as a specific marker of kidney function [2].
Due to its low molecular weight (13.3 kDa), Cystatin C
is freely filtered at the glomerulus, and is neither se-
creted nor reabsorbed in the renal tubules [3]. Although
Cystatin C has been shown to be a useful biomarker for
identifying renal injury post-surgery in a critical care set-
ting [4], at present there are no studies that have re-
ported the role of the parameter in patients undergoing
FURS. This makes cystatin C a novel and exiting pro-
spect for the monitoring of kidney stone patients.
Neutrophil gelatinase-associated lipocalin (NGAL) be-
longs to the lipocalin family, predominantly found
within neutrophils, but are also found in low levels in
the kidney, prostate and respiratory tract [5]. NGAL is
reported to be a modulator of the inflammatory re-
sponse, binding and attacking small lipophilic substances
in bacteria such as lipopolysaccharides and formyl pep-
tides [6]. Several studies have suggested NGAL may be a
useful kidney injury biomarker, particularly in patients
with nephrolithiasis or its associated pathologies [7–10].
NGAL has been reported as a potential renal injury bio-
marker in the early period after surgery and has a multi-
faceted role in inflammation and cancer [2, 11]. Notably,
in their study of urinary biomarkers in 30 patients post-
FURS, Benli et al (2017) reported a significant increase
in NGAL levels 2 h post-operatively [2]. This suggests
that the early post-operative rise in NGAL may provide
an opportunity for this biomarker to be utilised as part
of monitoring patients following FURS. In the present
study, we aim to expand on previous work undertaken
by others and to investigate changes in NGAL amongst
other biomarkers up to 4 h post-FURS.
Myeloperoxidase (MPO) is an enzyme which has been
shown to be expressed within neutrophils and mono-
cytes [12]. MPO produces hypochlorous acids (HOCl) as
part of the respiratory burst process, providing a highly
anti-microbial environment for bacteria and other path-
ogens [13, 14]. It is believed to have a role in cellular
homeostasis and is associated with inflammatory disease
development and progression; strong link has been
established in this regard, especially in the field of car-
diovascular disease (CVD) [15]. Hasmann et al. (2013)
have previously reported the role of MPO activity in
wound fluid, as a potential marker for infection, as it can
be appreciated that this biomarker may provide a more
rapid diagnosis, in comparison to traditional means of
testing for infection via microbiological methods and the
non-specific CRP [16]. MPO therefore warrants investi-
gation in the present study, as a potential biomarker for
infection or monitoring the respiratory burst in patients
post-FURS.
Sepsis, a potential life-threatening condition can be de-
fined as bacteriuria with systemic inflammatory response
syndrome (SIRS). It can be appreciated that sepsis can
be caused by an array of microorganisms such as bac-
teria, fungi and viruses. However, bacterial sepsis is by
far clinically the most diagnosed [17]. In sepsis, patho-
gens enter the blood stream where they can thrive and
release harmful infectious factors into the bloodstream
[18]. These products can stimulate the release of media-
tors of sepsis from biological cells such as monocytes,
macrophages, neutrophils and plasma cell precursors
[19]. The body’s attempt to fight the infection can in-
volve a systemic inflammatory response (SIRS), however,
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the resultant activation of inflammatory proteins can re-
sult in more extensive tissue and organ damage [20].
Procalcitonin (PCT), a calcitonin precursor, is upregu-
lated in response to such damage [21]. Raised blood
PCT levels indicate systemic bacterial infection. With
urosepsis a well-known complication of FURS, monitor-
ing PCT pre and post FURS may prove beneficial in
managing these patients [20, 21].
Several groups, including ours, have reported on the
effect of various urological and other surgical procedures
on post-operative routine and novel blood tests [22–27],
However, crucially, there are few studies into the effect
of FURS on kidney and infection biomarkers. Our study
aimed to evaluate the role of these biomarkers in order
to better establish their post-operative levels following
FURS for the treatment of nephrolithiasis.
Methods
Subject volunteers
Ethical approval for this study was received from the
Welsh Research Ethics Service (REC) 4 committee
(REC4: 12/WA/0117) and were carried out in accord-
ance with the ethical rules of the Helsinki Declaration
and Good Clinical Practice. As this is a single-centre ob-
servational clinical pilot-study, no sample size or power
calculation has been performed, and therefore all the
comparisons that will be considered are exploratory in
nature regardless of the significance level found. Thirty-
seven consecutive patients undergoing elective FURS for
the treatment of kidney stones were recruited (n = 37).
Twenty-four males and 13 females aged between 28 and
87 years (median 50 years) were recruited after receiving
written informed consent [23].
Flexible ureterorenoscopy (FURS)
FURS was performed as per local protocol at the Betsi
Cadwaladr University Health Board (BCUHB) Wrexham
Maelor, NHS hospital, North Wales, UK by a single con-
sultant surgeon who is an expert in the field, having
undertaken > 1000 FURS procedures. The Olympus
URF-P6 fibreoptic flexible Ureterorenoscope was used in
all cases. This has a working channel of 3.6Fr, working
length 670 mm, outer diameter 4.9Fr and outer diameter
insertion tube of 7.95Fr. Height of the irrigation fluid
was set to 80cmH2O and in all cases a 10/12Fr Colo-
plast ureteral access sheath was used, to standardise all
operations. As a result, injury to the distal tubule was
unrelated to the surgical procedure itself. The indication
to treat the patient with a 25mm stone was based on a
multi-disciplinary decision which was patient centred,
due to significant co-morbidities and as such not suit-
able for standard PCNL surgery. Clinical and surgical
information pertaining to the present study are pre-
sented in Table 1. Where possible, stones were sent for
composition analysis, using infrared spectroscopy at the
Leicester Royal Infirmary, UK [23].
Blood samples
Pre-operative (baseline) venous blood samples were col-
lected, with subsequent samples collected after FURS at
30, 120 and 240min. All samples were collected using
di-potassium ethylenediaminetetraacetic acid (EDTA)
and serum separator tube (SST) vacutainers. An 83%
compliance was obtained regarding blood sample collec-
tion at all time points, with the remaining 17% non-
compliance being due to difficulty (i.e. poor veins) with
the venesection.
Measurement of kidney biomarkers
Serum Cystatin C levels (mg/ml) were measured employing
a latex enhanced immunoturbidimetric methodology, using
a Thermo Fisher KoneLab 20 automated analyser. The
Cystatin C kits were supplied from Randox Laboratories
(Cat No: CYS4004).
Serum Neutrophil gelatinase-associated lipocalin (NGAL)
concentrations (ng/ml) was measured using commercially
available kits via quantitative sandwich enzyme immunoas-
says (ELISA) and were supplied by R&D Systems (Cat No:
DLCN20).
Measurement of infection biomarkers
Serum Myeloperoxidase (MPO) concentrations (ng/ml)
were measured using commercially available quantitative
sandwich enzyme immunoassay (ELISA) kits supplied by
R&D Systems (Cat No: DMYE00B).
Table 1 Clinical and surgical information




Median Stone Size 9.1 mm (range: 3.0 mm–25.00 mm)
Median Hounsfield Unit (HU) 1123 (range: 240–2224)
Stone location
Upper pole 15 patients
Mid pole 8 patients
Lower pole 14 patients
Median duration of laser
lithotripsy
9.54 min (range: 30 s-54.02 min)
Average energy 3232.7 J (Joule)
Mean pulse 6272.76 (number of pulses)
Median Operating time 57min (range: 20–175min)
Complete stone clearance 100% (n = 37), confirmed via imaging
at 3 months KUB XR if radio-opaque
stone and CT if lucent
Stent insertion 24 patients
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Plasma Procalcitonin (PCT) levels (ng/ml) were mea-
sured using commercially available kits (Cat No: 30450)
and a Biomerieux mini-VIDAS automated immunoana-
lyser, employing a one-step immunoassay method.
Statistical analysis
Statistical analysis was performed using SPSS (version
26). Testing for normality was carried out, and where
data was parametric, repeated measures one-way analysis
of variance (ANOVA) employed, using a 5% level of
significance. The Bonferroni method for pairwise com-
parisons between means was used for post-hoc testing.
Non-parametric data were analysed using the Friedman
test. Where this reached statistical significance, subse-
quent tests were performed with the Wilcoxon. Statistical
significance was defined when p ≤ 0.05.
All parametric data is presented as mean ± standard
deviation (S.D), whilst non-parametric results are pre-
sented as median ± interquartile range (Iqr).
Results
Effect on Cystatin C concentration
The results are expressed as mg/ml and represent changes
to serum Cystatin C following FURS (Fig. 1). Cystatin C
was measured as means of a kidney biomarker. Cystatin C
concentration did not change significantly from baseline
(2.95 ± 2.53mg/L) to 30min post-FURS (2.95 ± 2.66mg/L).
At 120min post FURS there was an increase in Cystatin C
levels (3.8 ± 2.36mg/L) followed by a decrease back toward
basal levels at 240min (2.94 ± 2.7mg/L). There were no
statistically significant changes in Cystatin C concentrations
following FURS (p = 0.462), as determined by the Friedman
test.
Effect NGAL
The results are expressed as ng/ml and represent
changes to serum NGAL following FURS (Fig. 2). Ini-
tially, there was an increase in NGAL concentration
from baseline (74.59 ± 9.4 ng/ml) up to 30 min (88.12 ±
11.25 ng/ml) post-FURS. At 120min (86.45 ± 11.45 ng/
ml) and 240min post FURS (77.63 ± 8.90 ng/ml) NGAL
concentration decreased toward basal levels. Friedman
analysis illustrated a significant increase in NGAL fol-
lowing FURS (p = 0.034). Post hoc analysis employing
the Wilcoxon test, confirmed a significant increase in
NGAL between baseline and 30min post-FURS (p =
0.047), although these changes did not correlate with
surgical time (p > 0.05).
Effect myeloperoxidase (MPO) concentration
The results are expressed as ng/ml and represent
changes to serum MPO following FURS (Fig. 3). MPO
was measured as means of a biomarker for infection. Ini-
tially, a decrease in MPO concentration from baseline
(11.66 ± 2.2 ng/ml) was seen, at 30 min (10.87 ± 2.2 ng/
ml) and 120 min (9.38 ± 1.6 ng/ml) post FURS. However,
a sharp increase occurred at 240 min (27.88 ± 1.3 ng/ml)
post FURS. However, statistical analysis found no signifi-
cant changes in MPO following FURS (p = 0.38), as de-
termined by the Friedman test.
Effect on PCT concentration
The results are expressed as ng/ml and represent changes
to plasma PCT following FURS (Fig. 4). PCT was measured
as means of a biomarker for infection. Only a negligible
change in PCT concentration between baseline (0.195 ±
0.002 ng/ml) up to 240min (0.188 ± 0.004 ng/ml) post-
Fig. 1 The effect of FURS, for the treatment of nephrolithiasis, on Cystatin C concentration. The points represent the median ± Iqr, p = 0.462 (n = 37)
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FURS was demonstrated. Analysis employing a paired t-test
showed no significant change in PCT concentration (p =
0.539). No samples analysis was undertaken for PCT at 30
and 120min post-operatively, due to the high cost of pur-
chasing assay kits and financial restrictions.
Stone analysis results
As per routine protocol, stone analysis was undertaken at
the Department of Pathology, Leicester Royal Infirmary
Hospital (UK). Stone composition results are presented in
Table 2.
Post-FURS complications
One female and two males developed a post-operative
urinary tract infection (UTI) with urinary retention. One
male patient developed urosepsis. Levels of Cystatin C
and NGAL for these patients are compared with the
average (n = 37) in Figs. 5, 6, 7, 8.
Fig. 2 The effect of FURS, for the treatment of nephrolithiasis, on NGAL concentration. The points represent the median ± Iqr, p = 0.034. * =Wilcoxon
test showed significance (p = 0.047) between levels at baseline and 30min post-operatively n = 37. Normal reference range = 42-177 ng/ml
Fig. 3 The effect of FURS for the treatment of nephrolithiasis on MPO concentration. The points represent the median ± Iqr, p = 0.38 (n = 37)
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A summary of the main findings from the study are
presented in Table 3.
Discussion
The aim of this prospective observational study was to
evaluate novel kidney and infection biomarkers, follow-
ing FURS in the management of nephrolithiasis. Cur-
rently, studies reporting on the role of biological
markers following FURS are limited.
Serum cystatin C is a non-glycosylated, 13.3-kDa pro-
tein belonging to cystatin protease inhibitors [28]. It has
shown promise as a replacement for serum creatinine as
a potential kidney biomarker [29, 30]. A 2002 meta-
analysis based on 46 studies concluded that cystatin C is
superior to creatinine for detection of compromised
renal function, as well as subsequent renal function
monitoring [31]. Although in our study there were no
significant changes in Cystatin C levels following FURS,
some interesting observations were noted when compar-
ing data of those who developed complications (patients
9, 10, 12 and 32) with those who did not (Fig. 5).
Specifically, patient 9 had developed 3 stones (size 2
mm, 20 and 5mm; comprising 100% calcium oxalate;
duration of procedure 28 min); patient 10 developed 1
stone (size 20 mm; comprising 80% calcium phosphate
and 20% calcium oxalate monohydrate; duration of pro-
cedure 32 min); and patient 12 developed 2 stones (size
20 and 17mm; comprising 100% calcium phosphate;
duration of procedure 98 min). With regards to patients
9, 10 and 12 none were first time stoners, none received
pre-operative stents and all three received a stent post-
operative. Interestingly, The Cystatin C levels of patients
who developed UTIs and subsequent urinary retention
(patient 9, 10, and 12) were higher to that of the normal
average patient response (Fig. 5). This biomarker, there-
fore, shows potential promise and warrants further
investigation, as for the patients who developed compli-
cations, Cystatin C levels rose sharply within a four-hour
time period, thus highlighting its sensitivity and potential
role as a marker of monitoring patients post FURS.
Recent research has suggested that NGAL is a useful
biomarker for measuring renal function and predicting
kidney injury [32, 33]. NGAL measured in the present
study demonstrated a significant increase in NGAL
levels post FURS (p = 0.034), with levels peaking be-
tween 30min and 2 h post treatment. Our results
compliment findings from a Dede et al. (2015) findings,
in 30 patients, that NGAL increased significantly 2 h
post-FURS [34]. Interestingly, the present study also
highlighted that patients who developed a complication
post-FURS (specifically patients 12 and 32; Fig. 6), re-
ported increased NGAL levels compared to the average
patient response. Although not confirmative, these initial
pilot data provide some interesting results and may war-
rant further investigation by recruiting larger cohorts.
With respect MPO, no significant changes were ob-
served in this biomarker following FURS. However, and
interesting trend of increased MPO levels were observed
and reported in patients who developed a complication
Fig. 4 The effect of FURS, for the treatment of nephrolithiasis, on PCT concentration. The points represent the mean ± S.D, p = 0.539(n = 37)
Table 2 Stone composition
Main constituent of stone(s) Patients
Calcium oxalate monohydrate 21
Calcium phosphate stones 7
Cystine stones 3
Calcium hydroxyl phosphate 3
Calcium-oxalate dihydrate stones 3
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post-FURS (specifically, patients 9, 12 and 32; Fig. 7).
Although MPO has been reported to be increased in
various inflammatory conditions and is considered a risk
marker for cardiovascular disease [35, 36], here we pro-
vide evidence that MPO may also be considered as a po-
tential biomarker for identifying patients with infectious
complications post FURS, although it is appreciated that
studies involving larger cohorts will be needed to valid-
ate this proposition.
Although PCT is considered a reliable biomarker that
displays greater specificity than other proinflammatory
markers, such as cytokines in identifying patients with
sepsis and aiding in the diagnosis of bacterial infections
[37]. The results from our pilot study were disappointing
Fig. 5 Comparison of Cystatin C concentration across all patients with those developing a complication. Patients 9 (male), 10 (male), and 12
(female) developed urinary tract infection (UTI) with urinary retention. Patient 32 (male) developed urosepsis (Average patient response n = 37).
Patients 9, 10 and 12 exhibited higher Cystatin C levels than the average group response
Fig. 6 Comparison of NGAL concentration across all patients with those developing a complication. Patients 9 (male), 10 (male), and 12 (female)
developed urinary tract infection (UTI) with urinary retention. Patient 32 (male) developed urosepsis (Average patient response n = 37). Patients 12
and 32 exhibited higher NGAL levels than the average group response. Missing data is representative of no sample collection or inadequate
sample volume for analysis
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in that PCT levels did not appear to significantly in-
crease in the four patients that developed complications.
Meisner et al. (1999) have previously reported on the
kinetic profiles of different biomarkers of bacterial infec-
tion, illustrating that PCT levels in plasma tend not to
peak until 10–12 h following infection [38, 39]. In the
present study, blood sampling was not undertaken
beyond > 4 h period due to ethical restirctions, which
may provide an explination as to why no significant
changes to PCT levels were reported. It is postulated
that the time frame (and a limitation of the present
study) was too short to see elevated PCT in patients with
complications [38]. However, in addition, further evi-
dence is provided here, in that that the other biomarkes
Fig. 7 Comparison of MPO concentration across all patients with those developing a complication. Patients 9 (male), 10 (male), and 12 (female)
developed urinary tract infection (UTI) with urinary retention. Patient 32 (male) developed urosepsis (Average patient response n = 37). Patients 12
and 32 exhibited higher MPO levels than the average group response. Missing data is representative of no sample collection or inadequate
sample volume for analysis
Fig. 8 Comparison of PCT concentration across all patients with those developing a complication. Patients 9 (male), 10 (male), and 12 (female)
developed urinary tract infection (UTI) with urinary retention. Patient 32 (male) developed urosepsis (Average patient response n = 37). Patients 9,
10 and 32 exhibited higher PCT levels than the average group response
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investigated in the present study (i.e. Cystatin C, NGAL
and MPO) may provide more sensitivity for detecting
complications ealier than PCT follwoing FURS.
A limiting factor associated with this study was the
relatively small number of patients recruited and the
number of sampling time points. It would have been
beneficial to have obtained further blood samples at time
point beyond 4 h (e.g. up to 24–48 h), but as these were
day-case patients obtaining additional samples was not
possible. In addition, the inclusion of a comparative con-
trol group, possibly involving patients undergoing other
urological procedures such as shock wave lithotripsy
(SWL) or TUR-B without fluid pressure to the control-
ling system (reflux out ruled) thereby identifying the po-
tential influence of anaesthesia may have been identified.
However, restriction to current ethics did not permit the
inclusion of such control groups.
In summary, we report that this study provides a basis
to undertake further investigations involving biomarkers
for monitoring FUR patients during the post-operative
period. It is envisaged that when these preliminary stud-
ies have been performed and authenticated in larger co-
horts, a panel of biomarkers (or biomarker profile) may
be produced that can help identify or predict those
patients that will develop post-operative complications
following FURS.
Conclusions
Changes seen to biomarkers such as Cystatin C, NGAL
and MPO in our observational clinical pilot-study may
warrant further investigation, involving larger cohorts, to
fully understand the role of these biomarkers and their
potential association with post-operative complications
which can develop following FURS.
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